MedTrace Logo

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

NCT00803907 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-06-13

No results posted yet for this study

Summary

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

Conditions

  • Carcinoma, Basal Cell

Interventions

DRUG

Imiquimod 5% cream

Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • E M macedo · University of Sao Paulo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-09-30
Completion
2013-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803907 on ClinicalTrials.gov